Publicaciones en colaboración con investigadores/as de University of Michigan Medical School (53)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium

    PLoS ONE, Vol. 18, Núm. 1 January

  3. Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

    International Journal of Epidemiology, Vol. 52, Núm. 2, pp. 355-376

  4. Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium

    eClinicalMedicine, Vol. 64

  5. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  6. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database

    JAMA dermatology, Vol. 159, Núm. 8, pp. 837-847

  7. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090

  8. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  9. Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: An international multi-centre observational cohort study

    eClinicalMedicine, Vol. 55

  10. Potential pitfalls in the use of real-world data for studying long COVID

    Nature Medicine

  11. Prevention of cardiorenal damage: importance of albuminuria

    European heart journal, Vol. 44, Núm. 13, pp. 1112-1123

  12. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet, Vol. 401, Núm. 10388, pp. 1584-1594

  13. Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK)

    Kidney International Reports, Vol. 8, Núm. 8, pp. 1542-1552

2022

  1. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 20, Núm. 5, pp. e440-e452

  2. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

    BJU International, Vol. 130, Núm. 5, pp. 592-603

  3. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 20, Núm. 6, pp. 558-567

  4. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  5. International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality

    npj Digital Medicine, Vol. 5, Núm. 1

  6. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin

    Clinical Genitourinary Cancer, Vol. 20, Núm. 2, pp. 165-175

2021

  1. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors

    European urology oncology, Vol. 4, Núm. 3, pp. 464-472